
Evonile Pharma Q2 FY27 Results: Standalone Net Loss ₹77.54 Crore on Total Income of ₹63.79 Crore
Evonile Pharma (NSE: NOVARTIND) reported a standalone net loss of ₹77.54 crore and total income of ₹63.79 crore for the quarter ended 30 Sep 2026, it said in a filing on 03 Nov 2026. The quarter's loss before tax was ₹101.06 crore after exceptional items of ₹682.6 million.
- Earnings
- Pharmaceuticals